C57BL/6NCya-Eif4a1em1flox/Cya
Common Name
Eif4a1-flox
Product ID
S-CKO-02176
Backgroud
C57BL/6NCya
Strain ID
CKOCMP-13681-Eif4a1-B6N-VA
When using this mouse strain in a publication, please cite “Eif4a1-flox Mouse (Catalog S-CKO-02176) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Eif4a1-flox
Strain ID
CKOCMP-13681-Eif4a1-B6N-VA
Gene Name
Product ID
S-CKO-02176
Gene Alias
Eif4, Ddx2a, BM-010
Background
C57BL/6NCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 11
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000163666
NCBI RefSeq
NM_144958
Target Region
Exon 2~4
Size of Effective Region
~1.3 kb
Overview of Gene Research
Eif4a1, a DEAD-box RNA-binding protein, is an essential eukaryotic translation initiation factor. It plays a crucial role in translation initiation by unwinding the secondary structure of mRNA upstream of the start codon, enabling ribosomal recruitment for downstream gene translation [2,4]. It is involved in pathways related to cell proliferation, such as the mTORC1 pathway [2,5,6].
Using mouse models to delete Eif4a1 in B cells, it was found that Eif4a1 is essential for B cell development and the germinal centre response. After B cell activation in vitro, Eif4a1 facilitates an increased rate of protein synthesis, MYC expression, and expression of cell cycle regulators [3]. In triple-negative breast cancer, IGF2BP2 recruits Eif4a1 to promote the translation output of CDK6, driving cell cycle progression [1].
In conclusion, Eif4a1 is vital for translation initiation and significantly impacts cell-related biological processes. Gene-knockout mouse models have revealed its role in B-cell-related processes and in triple-negative breast cancer, providing insights into its function in normal and disease-related conditions.
References：
1. Xia, Tian, Dai, Xin-Yuan, Sang, Ming-Yi, Wei, Ji-Fu, Ding, Qiang. 2023. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11, e2305142. doi:10.1002/advs.202305142. https://pubmed.ncbi.nlm.nih.gov/37983610/
2. Shichino, Yuichi, Yamaguchi, Tomokazu, Kashiwagi, Kazuhiro, Kuba, Keiji, Iwasaki, Shintaro. 2024. eIF4A1 enhances LARP1-mediated translational repression during mTORC1 inhibition. In Nature structural & molecular biology, 31, 1557-1566. doi:10.1038/s41594-024-01321-7. https://pubmed.ncbi.nlm.nih.gov/38773334/
3. Screen, Michael, Matheson, Louise S, Howden, Andrew Jm, Sansom, Owen, Turner, Martin. 2023. RNA helicase EIF4A1-mediated translation is essential for the GC response. In Life science alliance, 7, . doi:10.26508/lsa.202302301. https://pubmed.ncbi.nlm.nih.gov/38011999/
4. Kayastha, Forum, Herrington, Noah B, Kapadia, Bandish, Kellogg, Glen E, Gartenhaus, Ronald B. 2022. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma. In Molecular medicine (Cambridge, Mass.), 28, 101. doi:10.1186/s10020-022-00534-0. https://pubmed.ncbi.nlm.nih.gov/36058921/
5. Jiao, Dongyue, Sun, Huiru, Zhao, Xiaying, Wang, Chenji, Gao, Kun. 2024. mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cells. In eLife, 12, . doi:10.7554/eLife.92236. https://pubmed.ncbi.nlm.nih.gov/38738857/
6. Han, Luyang, Wu, Yuting, Liu, Fangming, Zhang, Hongbing. 2022. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest. In International journal of molecular sciences, 23, . doi:10.3390/ijms23136932. https://pubmed.ncbi.nlm.nih.gov/35805935/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.